Gitnux/Report 2026

Chemotherapy Industry Statistics

The global chemotherapy market reached $32.18 billion in 2025, explore the figures behind $35.24B in 2026, company profiles, and the 10.21% 2026–2035 forecast CAGR.
22Statistics
27Sources
4Sections
1Visuals
15mRead
How this report is researched
01Editorial Scope

An editor sets the topic, the inclusion criteria, and the evaluation framework before research starts.

02Source Research

AI search agents locate sources and extract each figure together with the document it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 32 days

01 Industry overview

The chemotherapy industry at a glance

The global chemotherapy market reached $32.18 billion in 2025 and is estimated at $35.24 billion in 2026, while targeted and immune-based alternatives increasingly reshape treatment demand.

$35.24B[9]
2026 chemotherapy market
10.21%[9]
2026–2035 forecast CAGR
38.12%[10]
Alkylating agents share, 2025
38.44%[10]
North America share, 2025
Market size
The global chemotherapy market was valued at $32.18 billion in 2025 and is estimated at $35.24 billion in 2026. A separate estimate places the 2025 market at $29.84 billion, reflecting differences in market definitions and coverage.[9][10]
Forecast & CAGR
Market Research Future forecasts growth from $35.24 billion in 2026 to $80.45 billion in 2035 at a 10.21% CAGR. Mordor Intelligence projects $32.68 billion in 2026 and $51.47 billion in 2031 at a 9.52% CAGR.[9][10]
Market share & regions
North America accounted for 38.44% of global chemotherapy-market revenue in 2025, making it the largest region. Asia-Pacific is forecast to be the fastest-growing region, with a projected 10.36% CAGR through 2031.[10]
Segmentation
Alkylating agents led by drug class with a 38.12% share in 2025, while oral therapies represented 50.74% of the market by administration route. Blood-cancer indications accounted for 26.05%, and adults held 56.05% by age group.[10]
Key players & concentration
Market Research Future identifies Roche, Pfizer, Bristol Myers Squibb, Novartis, Teva and Cipla among the principal chemotherapy companies. Grand View Research lists 10 major oncology-drug players, including Roche, Merck, AstraZeneca, Bristol Myers Squibb, Pfizer, Novartis, Johnson & Johnson, Eli Lilly, GSK and Amgen.[9][11]
Pricing
AARP reports that chemotherapy for uninsured U.S. patients commonly costs $8,000–$50,000 per treatment cycle, with complete courses potentially exceeding $200,000. Actual prices vary by drug regimen, cancer type, treatment setting and insurance coverage.[12]
Trends, drivers & challenges
Persistent cancer incidence and continued use of cytotoxic drugs in combination regimens support demand, while oral formulations and Asian API scale-up broaden access. The industry faces shortages of legacy generic drugs, stricter hazardous-waste requirements and competition from immuno-oncology research.[10][13]
Consumer behavior & competition
Oral chemotherapy represented 50.74% of the global market in 2025, indicating substantial demand for non-intravenous treatment options. Hospital pharmacies accounted for 72.8% of the broader oncology-drugs market, while branded products held 68.5%, showing the importance of institutional purchasing and branded competition.[10][11]
M&A
In March 2026, Merck agreed to acquire Terns Pharmaceuticals for approximately $6.7 billion in cash, or $53 per share. The transaction was intended to strengthen Merck’s oncology portfolio ahead of Keytruda’s expected patent expiry in 2028.[14]
Regulation
The FDA granted accelerated approval on October 19, 2026, for Jemperli in certain locally advanced rectal cancers, potentially allowing some patients to avoid chemotherapy, radiation and surgery. The agency also recorded multiple 2026 oncology approvals involving chemotherapy combinations, including fluoropyrimidine- and platinum-containing regimens.[15]
Latest news
In July 2026, U.S. cancer centers reported shortages of carboplatin, cisplatin and ifosfamide, raising concerns about treatment delays or rationing. In October 2026, the FDA approved an immunotherapy option that may let some eligible rectal-cancer patients avoid chemotherapy altogether.[13][15]

02 Ranking

Top 10 Companies in the Chemotherapy Industry

The leading companies in the chemotherapy industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 21, 2026 · Next review December 21, 2026

Verdict

Eli Lilly and Company stands out for oncology medicines because it reported $5.723bn in 2025 worldwide Verzenio revenue, while Roche focuses on oncology medicines and diagnostics since it reported $7.835bn in 2025 oncology sales.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in oncology drug development

    Eli Lilly and Company

    US

    Ranked #1 · 9.6 · Oncology drug development

    Why we picked it: Lilly’s oncology medicines line includes Verzenio, backed by an an operating margin of 40.4% in 2025.

  2. Leader in oncology medicines & diagnostics

    Roche

    CH

    Ranked #2 · 9.1 · Oncology medicines & diagnostics

    Why we picked it: Roche’s global oncology medicines and diagnostics draw on an an R&D budget of 19.8% of revenue in 2025.

  3. #3 overall

    Novartis

    CH

    Ranked #3 · 9.1 · Oncology drug development

    Why we picked it: Novartis reports an operating margin of 32.4% in 2025 while sustaining oncology-focused R&D at 20.5% of revenue.

Pick 1 is the #1 company overall. Pick 2 is the highest-ranked company in the top 5 that adds a new segment; no further segment places in the top 5, so pick 3 follows rank.

Full ranking

Sort by
Top 10 companies in the chemotherapy industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Eli Lilly and Company

Oncology drug development · US

9.6
2

Roche

Oncology medicines & diagnostics · CH

9.1
3

Novartis

Oncology drug development · CH

9.1
4

AstraZeneca

Oncology drug development · GB

9.0
5

Johnson & Johnson

Oncology drug development · US

9.0
6

Merck

Global oncology medicines, led by Keytruda · US

8.7
7

Pfizer

Global oncology medicines and manufacturing · US

8.7
8

Amgen

Oncology biologics and supportive care · US

8.6
9

Sun Pharmaceutical Industries

Generic and specialty oncology medicines · IN

8.0
10

Teva Pharmaceutical Industries

Generic and specialty oncology medicines · IL

7.9

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 21, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 21). Top 10 companies in the chemotherapy industry. In Chemotherapy Industry Statistics. Gitnux. https://gitnux.org/chemotherapy-industry-statistics/#top-companies

report visual · Comparison

Annual growth in global oncology medicine spending

Annual growth in global oncology medicine spending: 14% in 2024, 14% in 2024.

2025 (forecast)17%
202414%
2026 (forecast)14%
2027 (forecast)10%
2028 (forecast)10%
2029 (forecast)8%
source-verifiediqvia.com2029

04 Statistics

Market Intelligence

Ontario systemic-therapy activity rose from 2015 to 2022, with systemic-treatment visits increasing from 129,380 to 165,149, and total outpatient medical-oncology clinic visits reaching 174,630 by 2022.

Demand shifts in the chemotherapy industry

  • The share of patients receiving systemic therapy increased for melanoma from 25.7% in 2015 to 47.2% in 2022; no newer measurement was identified.[1]
  • Systemic-treatment visits increased from 129,380 in 2015 to 165,149 in 2022, a 27.9% rise, among Ontario adults with seven specified cancers; no newer measurement was identified.[2]
  • Total outpatient medical-oncology clinic visits rose from 131,950 in 2015 to 174,630 in 2022, a 32.3% increase; no newer measurement was identified.[2]

05 Statistics

Operating Benchmarks

Oncology Care Model episode data show chemotherapy-linked acute-care exposure, including emergency-department visits without hospital admission at 7.6% and during the intervention period at 15.9% (Medicare claims covered 2014–2022).

Operating metrics used in the chemotherapy industry

  • 7.6% of Oncology Care Model intervention episodes had a chemotherapy-associated emergency-department visit without hospital admission, versus 8.2% for comparison episodes; Medicare claims covered 2014–2022.[3]
  • 9.7% of Oncology Care Model intervention episodes had a chemotherapy-associated emergency-department visit resulting in hospital admission, versus 9.3% for comparison episodes; Medicare claims covered 2014–2022.[3]
  • 15.9% of Oncology Care Model intervention episodes had a chemotherapy-associated emergency-department visit during the intervention period, versus 16.0% for comparison episodes; Medicare claims covered 2014–2022.[3]
  • 12.0% of Oncology Care Model intervention episodes had a chemotherapy-associated hospitalization during the intervention period, versus 11.3% for comparison episodes; Medicare claims covered 2014–2022.[3]

06 Statistics

People & Workforce

Oncology staffing appears concentrated in surveyed roles, with 95% of Oncology Nursing Society members identifying oncology as their primary specialty in 2024 and 17,094.5 registered nurses reporting oncology as primary.

Employment and hiring in the chemotherapy industry

  • 95% of Oncology Nursing Society members identified oncology as their primary specialty in 2024; 60% identified medical oncology.[4]
  • 17,094.5 registered nurses identified oncology as their primary specialty in 2024, representing 3.1% of actively employed U.S. RNs in the survey.[5]
  • 5,099 licensed practical or vocational nurses identified oncology as their primary specialty in 2024, representing 0.8% of actively employed U.S. LPNs/LVNs surveyed.[6]
  • 54% of Oncology Nursing Society members reported staff nurse as their primary nursing title in 2024, while 8% reported nurse practitioner.[4]

Skills and certification in the chemotherapy industry

  • 60% of Oncology Nursing Society members identified medical oncology as their primary specialty in 2024.[4]
  • 95% of Oncology Nursing Society members reported oncology as their primary specialty in 2024, including 60% in medical oncology.[4]
  • 33,199 nurses held the Oncology Certified Nurse credential in 2024, the largest individual credential category reported by ONCC.[7]
  • 44,894 oncology-certified nurses held active Oncology Nursing Certification Corporation credentials in 2024 across eight listed credential categories.[7]

07 Statistics

Risk & Compliance

Regulatory timing is explicit for chemotherapy providers, including the 60 calendar days HIPAA maximum for notifying affected individuals after unsecured-PHI breach discovery and a 15 calendar day PHI-access request response limit under the 2026 final rule.

Regulation and licensing in the chemotherapy industry

  • January 2, 2025 was the implementation date for CMS’s updated Medicare payment guidance covering chemotherapy-administration and infusion services; the guidance applies in the United States.[3]
  • 1 initial chemotherapy-administration service code may be reported per patient encounter unless medically necessary services occur at separate intravenous access sites; CMS Medicaid NCCI policy, U.S., revised January 1, 2024.[3]
  • 96401–96425 are chemotherapy-administration codes reportable by physicians in office settings, while facility settings follow separate reporting rules; CMS Medicaid NCCI policy, U.S., revised January 1, 2024.[3]

Client data and confidentiality in the chemotherapy industry

  • 60 calendar days is the maximum period for notifying affected individuals after discovery of an unsecured-PHI breach; this HIPAA requirement applies to U.S. covered chemotherapy providers and business associates.[8]
  • 500 affected individuals is the threshold requiring covered entities to notify the HHS Secretary without unreasonable delay and no later than 60 days after breach discovery; the rule covers U.S. chemotherapy providers subject to HIPAA.[8]
  • 15 calendar days is the new maximum response period for a patient’s PHI-access request under HHS’s 2026 HIPAA final rule; chemotherapy providers covered by HIPAA in the United States are within scope.[8]
  • 60 calendar days is the maximum extension for responding to an individual’s PHI-access request under HHS’s 2026 HIPAA final rule; the rule applies to covered chemotherapy providers in the United States.[8]

Key questions about the chemotherapy industry

How large is the global chemotherapy market in 2026?
The global chemotherapy market is estimated at $35.24 billion in 2026.
What growth rate is forecast for chemotherapy over the long term?
From 2026 to 2035, the market is forecast to grow at a 10.21% CAGR, from $35.24 billion in 2026 to $80.45 billion in 2035.
Which companies lead the chemotherapy industry?
Eli Lilly and Company stands out for oncology medicines because it reported $5.723bn in 2025 worldwide Verzenio revenue, while Roche focuses on oncology medicines and diagnostics since it reported $7.835bn in 2025 oncology sales.
How are administration routes changing chemotherapy demand?
Oral therapies represented 50.74% of the market by administration route in 2025, indicating a shift away from infusion-only care.
Which drug class dominates chemotherapy in 2025?
Alkylating agents led by drug class held a 38.12% share in 2025.
What compliance timelines affect chemotherapy providers handling patient data?
Under the HIPAA requirement in scope, providers have 15 calendar days for PHI-access request responses under the 2026 final rule, with up to a 60 calendar days extension.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 21). Chemotherapy Industry Statistics. Gitnux. https://gitnux.org/chemotherapy-industry-statistics
MLA
Samuel Norberg. "Chemotherapy Industry Statistics." Gitnux, 21 Nov 2026, https://gitnux.org/chemotherapy-industry-statistics.
Chicago
Samuel Norberg. 2026. "Chemotherapy Industry Statistics." Gitnux. https://gitnux.org/chemotherapy-industry-statistics.